The love of a lifetime: 5-HT in the cardiovascular system

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 296, Issue 2, 2009, Pages

  Watts, Stephanie W ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Serotonin

Indexed keywords

1 ISOPROPYL 6 METHYLERGOLINE 8 CARBOXYLIC ACID 2 HYDROXY 1 METHYLPROPYL ESTER; AMINE OXIDASE (FLAVIN CONTAINING); NITRIC OXIDE SYNTHASE; RITANSERIN; SEROTONIN; SEROTONIN 2B RECEPTOR; SEROTONIN RECEPTOR;

BLOOD PRESSURE; BLOOD PRESSURE REGULATION; BLOOD VESSEL TONE; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR SYSTEM; CONFERENCE PAPER; ENZYME ACTIVITY; GASTROINTESTINAL TRACT FUNCTION; HUMAN; HYPERTENSION; MOOD; MUSCLE ISOMETRIC CONTRACTION; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SATIETY; SMOOTH MUSCLE FIBER; ANIMAL; ARTICLE; AWARDS AND PRIZES; HISTORY; METABOLISM; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION; VASOCONSTRICTION;

ANIMALS; AWARDS AND PRIZES; BLOOD PRESSURE; CARDIOVASCULAR SYSTEM; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; HYPERTENSION; RECEPTOR, SEROTONIN, 5-HT2B; SEROTONIN; SIGNAL TRANSDUCTION; VASOCONSTRICTION;

EID: 61949351577     PISSN: 03636119     EISSN: 15221490     Source Type: Journal    
DOI: 10.1152/ajpregu.90676.2008     Document Type: Conference Paper

References (39)

1. Abenhaim L, Moride Y, Brenot F, Rich S, Benichous J, Kurz X, Higenbottam T, Oakley C, Wouters E, Aubier M, Simonneau G, Begaud B. Appetite-suppressant drugs and the risk of pulmonary hypertension. N Engl J Med 335: 609-616, 1996. (Pubitemid 26277950)
2. Azmitia EC. Modern views on an ancient chemical: serotonin effects on cell proliferation, maturation and apoptosis. Brain Res Bull 56: 413-424, 2001.
3. Banes AB, Watts SW. Upregulation of arterial serotonin 1B and 2B receptors in deoxycorticosterone acetate-salt hypertension. Hypertension 39: 394-398, 2002.
4. 1-adrenergic receptors. Clin Pharmacol Ther 49: 377-384, 1991.
5. Brenner B, Harney JT, Ahmed BA, Jeffus BC, Unal R, Mehta JL, Kilic F. Plasma serotonin levels and the platelet serotonin transporter. J Neurochem 102: 206-215, 2007. (Pubitemid 46906271)
6. Cohen ML, Fuller RW, Kurz KD. Evidence that blood pressure reduction by serotonin antagonists is related to α-receptor blockade in spontaneously hypertensive rats. Hypertension 5: 676-681, 1983.
7. Cohen ML, Schenck KW, Mabry TE, Nelson DL, Audia JE. LY272015, a potent, selective and orally active 5-HT2B receptor antagonist. J Serotonin Res 3: 131-144, 1996.
8. Collis MG, Vanhoutte PM. Vascular reactivity of isolated perfused kidneys from male and female spontaneously hypertensive rats. Circ Res 41: 759-767, 1977.
9. Cote F, Fligney C, Fromes Y, Mallet J, Vodjdani G. Recent advances in understanding serotonin regulation of cardiovascular function. Trends Mol Med 10: 232-238, 2004. (Pubitemid 38581796)
10. Diaz J, Ni W, King A, Fink GD, Watts SW. 5-hydroxytryptamine lowers blood pressure in normotensive and hypertensive rats. J Pharmacol Exp Ther 325: 1031-1038, 2008.
11. Doggrell SA. The role of 5-HT on the cardiovascular and renal systems and the clinical potential of 5-HT modulation. Expert Opin Investig Drugs 12: 805-823, 2003.
12. Erspamer V, Asero B. Identification of enteramine, the specific hormone of the enterochromaffin cell system, as 5-hydroxytryptamine. Nature 169: 800-801, 1952.
13. Fetkovska N, Amstein R, Ferracin F, Regenass M, Buhler FR, Pletscher A. 5-Hydroxytryptamine kinetics and activation of blood platelets in patients with essential hypertension. Hypertension 15: 267-273, 1990. (Pubitemid 20097454)
14. Foguet M, Hoyer D, Ardo LA, Parekh A, Kluxen FW, Kalkman HO, Stuhmer W, Lubbert H. Cloning and functional characterization of the rat stomach fundus serotonin receptor. EMBO J 11: 3481-3487, 1992.
15. Green RA. Neuropharmacology of 5-hydroxytryptamine. Br J Pharmacol 146: 306-312, 2006.
16. Gustafsson BI, Tommeras K, Nordrum I, Loennechen JP, Brunsvik A, Solligard E, Fossmark R, Bakke I, Syversen U, Waldum H. Long-term serotonin administration induces heart valve disease in rats. Circulation 111: 1517-1522, 2005. (Pubitemid 40470647)
17. Hoyer D, Hannon JP, Martin GR. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav 71: 533-554, 2002. (Pubitemid 34219205)
18. Kaumann AJ, Levy FO. 5-Hydroxytryptamine receptors in the human cardiovascular system. Pharmacol Ther 111: 67-76, 2006.
19. 2F) from the rat stomach fundus. Mol Pharmacol 42: 549-557, 1992. (Pubitemid 23027614)
20. MacLean MR, Herve P, Eddahibi S, Adnot S. 5-Hydroxytryptamine and the pulmonary circulation: receptors, transporters and relevance to pulmonary arterial hypertension. Br J Pharmacol 131: 161-168, 2000.
21. McGregor DD, Smirk FH. Vascular reactivity to 5-hydroxytryptamine and hypertension in the rat. Naunyn Schmiedebergs Arch Pharmacol 272: 101-116, 1970.
22. Ni W, Geddes TJ, Priestley JRC, Szasz T, Kuhn DM, Watts SW. The existence of a local serotonergic system in peripheral arteries. Br J Pharmacol 154: 663-674, 2008.
23. Ni W, Li MW, Thakali K, Fink GD, Watts SW. The fenfluramine metabolite (+)-norfenfluramine is vasoactive. J Pharmacol Exp Ther 309: 845-852, 2004. (Pubitemid 38542641)
24. Ni W, Thompson JM, Northcott CA, Lookingland K, Watts SW. The serotonin transporter is present and functional in peripheral arterial smooth muscle. J Cardiovasc Pharmacol 43: 770-781, 2004. (Pubitemid 38679598)
25. Ni W, Watts SW. 5-Hydroxytryptamine in the cardiovascular system: focus on the serotonin transporter (SERT). Clin Exp Pharmacol Physiol 33: 575-583, 2006. (Pubitemid 43894017)
26. Page IH, McCubbin JW. Modification of vascular responses to serotonin by drugs. Am J Physiol 174: 436-440, 1953a.
27. Page IH, McCubbin JW. The variable arterial pressure response to serotonin in laboratory animals and man. Circ Res 1: 354-362, 1953b.
28. Pomfret DW, Schenck KW, Fludzinski P, Cohen ML. Interaction of 5-hydroxykynurenamine, L-kynurenine and kynuramine with multiple serotonin receptors in smooth muscle. J Pharmacol Exp Ther 241: 465-471, 1987. (Pubitemid 17111549)
29. Rapport MM, Green AA, Page IH. Serum vasoconstrictor (serotonin) IV. Isolation and characterization. J Biol Chem 176: 1243-1251, 1948.
30. 2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 102: 2836-2841, 2000.
31. 2B receptor function is enhanced in the Nω-nitro-L-arginine hypertensive rat. J Pharmacol Exp Ther 303: 179-187, 2002.
32. Turla MD, Webb RC. Vascular Responsiveness to 5-hydroxytryptamine in experimental hypertension. In: The Peripheral Actions of 5-Hydroxytryptamine, edited by Fozard JR. Oxford, UK: Oxford University Press, 1989, p. 327-353.
33. Vanhoutte P, Amery A, Birkenhager W, Breckenridge A, Buhler F, Distler A, Dormandy J, Doyle A, Frohlich E, Hansooon L, Hedner T, Hollenberg N, Jensen HE, Lund-Johansen P, Meyer PL, Opie L, Robertson I, Safar M, Schalekamp M, Symoens J, Trap-Jensen J, Zanchetti A. Serotoninergic mechanisms in hypertension. Focus on the effects of ketanserin. Hypertension 11: 111-133, 1988. (Pubitemid 18086318)
34. Villalon CM, Centurion D. Cardiovascular responses produced by 5-hydroxytryptamine: a pharmacological update on receptors/mechanisms involved and therapeutic implications. Naunyn Schmiedebergs Arch Pharmacol 376: 45-63, 2007.
35. 2B receptor antagonist LY272015 inhibits 5-HT-induced contraction in the aorta of mineralocorticoid-salt hypertensive rats. J Serotonin Res 4: 197-206, 1997.
36. Watts SW. 5-HT in systemic hypertension: foe, friend or fantasy? Clin Sci (Lond) 108: 399-412, 2005.
37. 2B-receptor antagonist LY272015 is antihypertensive in DOCA-salt-hypertensive rats. Am J Physiol Heart Circ Physiol 276: H944-H952, 1999.
38. 2B receptor mediates contraction to 5-HT in the mesenteric artery of DOCA-salt hypertensive rats. Hypertension 26: 1056-1059, 1995. (Pubitemid 3014520)
39. Webb RC. Increased vascular sensitivity to serotonin and methysergide in hypertension in rats. Clin Sci 63: 73s-75s, 1982.